Skip to main content
Fig. 1 | Breast Cancer Research

Fig. 1

From: Simultaneous targeting of HER family pro-survival signaling with Pan-HER antibody mixture is highly effective in TNBC: a preclinical trial with PDXs

Fig. 1

Amplification/overexpression of the HER family correlates with poor prognosis in breast cancer. a Data acquired from cBioPortal (NCI-GDC Data Portal) for Cancer Genomics showing the percentages of genetic modifications of different components of the HER family among breast cancer patients (8824 breast cancer patients, a total of 9052 samples from 12 studies). b Alterations of HER family members portends significantly poorer overall survival in TNBC patients [Kaplan-Meir analysis tools: Refs. [23, 24]]

Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us